Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs

Eri Matsuki, MD PhD MPH, Masatoshi Sakurai, MD PhD, Daiki Karigane, MD, Hidenori Kasahara, MD, Taku Kikuchi, MD, Takayuki Shimizu, MD PhD, Kenji Yokoyama, MD PhD, Takehiko Mori, MD PhD, Shinichiro Okamoto, MD PhD

Blood (2016) 128 (22): 1887.

https://doi.org/10.1182/blood.V128.22.1887.1887

Published: 2016

Journal Articles

Effects of Daily Aspirin on Cancer Incidence and Mortality in the Japanese

Kenji Yokoyama, MD PhD, Naoki Ishizuka, PhD, Naomi Uemura, MD PhD, Yuji Mizokami, MD PhD, Hideyuki Hiraishi, MD PhD, Tamio Teramoto, MD PhD, Kazuyuki Shimada, MD PhD, Yasuo Ikeda, MD PhD

Blood (2015) 126 (23): 2322.

https://doi.org/10.1182/blood.V126.23.2322.2322

Published: 2015

Journal Articles

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Rachel K Wee, Hiroyuki Takamatsu, MD PhD, Ryoichi Murata, MD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Naoki Takezako, MD PhD, Shigeki Ito, MD PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, MD PhD, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, MD PhD, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2015) 126 (23): 1782.

https://doi.org/10.1182/blood.V126.23.1782.1782

Published: 2015

Journal Articles

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma

Hiroyuki Takamatsu, MD PhD, Ryoichi Murata, MD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Naoki Takezako, MD PhD, Shigeki Ito, MD, PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, MD PhD, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, MD PhD, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2014) 124 (21): 2003.

https://doi.org/10.1182/blood.V124.21.2003.2003

Published: 2014

Journal Articles

Subcutaneous Preadipocytes Are Ideal Candidate To Produce A Large Number Of Functional Platelets In a Culture System

Yukako Ono-Uruga, MD, PhD, Tatsuya Tanaka, Atsuko Igari, Takanori Moriki, MD, PhD, Kenji Yokoyama, MD, PhD, Takeru Zama, MD, PhD, Tadashi Horiuchi, PhD, Mitsuru Murata, MD, PhD, Yasuo Ikeda, MD, PhD, Toshio Suda, MD, PhD, Yumiko Matsubara, PhD

Blood (2013) 122 (21): 3271.

https://doi.org/10.1182/blood.V122.21.3271.3271

Published: 2013

Journal Articles

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Eri Matsuki, MD, PhD, Taku Kikuchi, MD, Norisato Hashimoto, MD, Shunsuke Souma, MD, Sumiko Kohashi, MD, Takaaki Toyama, MD, Masatoshi Sakurai, MD, Daiki Karigane, MD, Daichi Abe, MD, Takayuki Shimizu, MD, PhD, Kenji Yokoyama, MD, PhD, Hideaki Nakajima, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2013) 122 (21): 1800.

https://doi.org/10.1182/blood.V122.21.1800.1800

Published: 2013

Journal Articles

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Eri Matsuki, MD, PhD, Yukako Ono, MD, Koharu Tonegawa, Masatoshi Sakurai, MD, Hiroyoshi Kunimoto, MD, Jo Ishizawa, MD, PhD, Norisato Hashimoto, MD, Takayuki Shimizu, MD, PhD, Akiko Yamane, MD, PhD, Maiko Matsushita, MD, PhD, Kenji Yokoyama, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2012) 120 (21): 2788.

https://doi.org/10.1182/blood.V120.21.2788.2788

Published: 2012

Journal Articles

Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,

Eri Matsuki, MD, PhD, Yukako Ono, MD, Masatoshi Sakurai, MD, Hiroyoshi Kunimoto, MD, Jo Ishizawa, MD, PhD, Takayuki Shimizu, MD, PhD, Akiko Yamane, MD, PhD, Maiko Matsushita, MD, PhD, Kenji Yokoyama, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2011) 118 (21): 3765.

https://doi.org/10.1182/blood.V118.21.3765.3765

Published: 2011

Journal Articles

Establishment of a Novel Cell Line of Plasmablastic Lymphoma with Loss of p16 Tumor Suppressor Protein and Overexpression of MDR

Eri Matsuki, MD, Yoshitaka Miyakawa, MD, PhD, Shuichi Asakawa, Yuiko Tsukada, MD, Kenji Yokoyama, MD, PhD, Jun Kudoh, Shinichiro Okamoto, MD, PhD

Blood (2010) 116 (21): 4451.

https://doi.org/10.1182/blood.V116.21.4451.4451

Published: 2010

Journal Articles

GSK-3β Negatively Regulates Megakaryocyte and Platelet Production in an In Vitro Human Bone Marrow Mononuclear Cell-Derived Differentiation System.

Yumiko Matsubara, PhD, Mitsuru Murata, MD, Hidenori Suzuki, PhD, Kenji Yokoyama, MD, Hiroaki Ishihara, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD, Yasuo Ikeda, MD

Blood (2007) 110 (11): 4036.

https://doi.org/10.1182/blood.V110.11.4036.4036

Published: 2007

NARROW

Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs

Effects of Daily Aspirin on Cancer Incidence and Mortality in the Japanese

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma

Subcutaneous Preadipocytes Are Ideal Candidate To Produce A Large Number Of Functional Platelets In a Culture System

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,

Establishment of a Novel Cell Line of Plasmablastic Lymphoma with Loss of p16 Tumor Suppressor Protein and Overexpression of MDR

GSK-3β Negatively Regulates Megakaryocyte and Platelet Production in an In Vitro Human Bone Marrow Mononuclear Cell-Derived Differentiation System.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only